Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRELEGY ELLIPTA vs Non-ELLIPTA Triple Therapy in COPD (LEGEND)
NCT03949842Phase 4Withdrawn
- Sponsor
- GSK
- Start
- Jun 2019
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoint: Annualized rate of moderate, severe COPD exacerbations at 104 weeks. Planned start Jun 2019; status: withdrawn.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03949842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949842.